Key result
Carriers of the CES1 143E-allele had significantly greater levels of clopidogrel active metabolite (P=0.001) and better clopidogrel response measured by platelet aggregation.
Why the study?
Does the CES1 G143E variant increase clopidogrel active metabolite levels and improve platelet response in patients treated with clopidogrel?
Population
916 participants, comprising 566 from the Pharmacogenomics of Anti-Platelet Intervention study and 350…
Comparison
Presence of the CES1 G143E variant vs Non-carriers of the CES1 143E-allele
Design
Cohort
Authors
Loading...
CES1 143E-allele carriage was associated with greater clopidogrel response; extends candidate-gene evidence but leaves clinical utility open.
Observational (n=916)
Does the CES1 G143E variant increase clopidogrel active metabolite levels and improve platelet response in patients treated with clopidogrel?
p-value: p=0.001
The CES1 G143E variant is associated with higher clopidogrel active metabolite levels and greater platelet inhibition, suggesting it is an important genetic determinant of clopidogrel efficacy.
Lewis et al. (2012) conducted an observational in Coronary heart disease (n=916). CES1 G143E variant (143E-allele) vs. Non-carriers of the 143E-allele was evaluated on Clopidogrel active metabolite levels and on-clopidogrel ADP-stimulated platelet aggregation (p=0.001). Carriers of the CES1 143E-allele had significantly greater levels of clopidogrel active metabolite (P=0.001) and better clopidogrel response measured by platelet aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: